These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
206 related articles for article (PubMed ID: 17962945)
1. Anti-inflammatory pretreatment enables an efficient dendritic cell-based immunotherapy against established tumors. Chiarella P; Vulcano M; Bruzzo J; Vermeulen M; Vanzulli S; Maglioco A; Camerano G; Palacios V; Fernández G; Brando RF; Isturiz MA; Dran GI; Bustuoabad OD; Ruggiero RA Cancer Immunol Immunother; 2008 May; 57(5):701-18. PubMed ID: 17962945 [TBL] [Abstract][Full Text] [Related]
2. [Reversion of the immunological eclipse and therapeutic vaccination against cancer in an experimental model]. Chiarella P; Vulcano M; Laborde E; Vermeulen M; Bruzzo J; Rearte B; Bustuoabad OD; Ruggiero RA Medicina (B Aires); 2007; 67(1):44-8. PubMed ID: 17408020 [TBL] [Abstract][Full Text] [Related]
3. Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines. Zitvogel L; Mayordomo JI; Tjandrawan T; DeLeo AB; Clarke MR; Lotze MT; Storkus WJ J Exp Med; 1996 Jan; 183(1):87-97. PubMed ID: 8551248 [TBL] [Abstract][Full Text] [Related]
4. Phenotypic profile of dendritic and T cells in the lymph node of Balb/C mice with breast cancer submitted to dendritic cells immunotherapy. da Cunha A; Antoniazi Michelin M; Cândido Murta EF Immunol Lett; 2016 Sep; 177():25-37. PubMed ID: 27423825 [TBL] [Abstract][Full Text] [Related]
5. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen. Ojima T; Iwahashi M; Nakamura M; Matsuda K; Naka T; Nakamori M; Ueda K; Ishida K; Yamaue H Int J Oncol; 2006 Apr; 28(4):947-53. PubMed ID: 16525645 [TBL] [Abstract][Full Text] [Related]
6. DC vaccination with anti-CD25 treatment leads to long-term immunity against experimental glioma. Maes W; Rosas GG; Verbinnen B; Boon L; De Vleeschouwer S; Ceuppens JL; Van Gool SW Neuro Oncol; 2009 Oct; 11(5):529-42. PubMed ID: 19336528 [TBL] [Abstract][Full Text] [Related]
7. [Study on the specific immunity of dendritic cell vaccine loading human umbilical vein endothelial cell antigen against U14 cervical cancer]. Zhao J; Zhai JM; Lu J; Yang HY; Huang YT; Li S; Dong ZM; Zhang X Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2009 Mar; 25(3):196-200. PubMed ID: 19257979 [TBL] [Abstract][Full Text] [Related]
8. [Unveiling antigens in a non-immunogenic spontaneous murine tumor using a dendritic cell based vaccine]. Reffo VL; Chiarella P; Bruzzo J; Bustuoabad OD; Ruggiero RA Medicina (B Aires); 2008; 68(4):301-4. PubMed ID: 18786887 [TBL] [Abstract][Full Text] [Related]
9. Enhancing Dendritic Cell-based Immunotherapy with IL-2/Monoclonal Antibody Complexes for Control of Established Tumors. Kim MT; Richer MJ; Gross BP; Norian LA; Badovinac VP; Harty JT J Immunol; 2015 Nov; 195(9):4537-44. PubMed ID: 26408669 [TBL] [Abstract][Full Text] [Related]
10. [Systemic inflammation and experimental cancer in a murine model]. Bruzzo J; Chiarella P; Fernández G; Bustuoabad OD; Ruggiero RA Medicina (B Aires); 2007; 67(5):469-74. PubMed ID: 18051231 [TBL] [Abstract][Full Text] [Related]
11. Dendritic cells in antitumor immune responses. II. Dendritic cells grown from bone marrow precursors, but not mature DC from tumor-bearing mice, are effective antigen carriers in the therapy of established tumors. Gabrilovich DI; Nadaf S; Corak J; Berzofsky JA; Carbone DP Cell Immunol; 1996 May; 170(1):111-9. PubMed ID: 8665591 [TBL] [Abstract][Full Text] [Related]
12. Eliciting T cell immunity against poorly immunogenic tumors by immunization with dendritic cell-tumor fusion vaccines. Wang J; Saffold S; Cao X; Krauss J; Chen W J Immunol; 1998 Nov; 161(10):5516-24. PubMed ID: 9820528 [TBL] [Abstract][Full Text] [Related]